Arthur Tzianabos, Ph.D.


Dr. Arthur Tzianabos is a venture partner at 5AM Ventures and is the CEO of Lifori Immunotherapeutics. He is the chair of the Board of Directors at Homology Medicines, where he previously served as president and CEO, leading the company from inception through a successful public offering. While at Homology, Arthur led efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. He previously was president and chief scientific officer of OvaScience, where he translated early science into treatments for fertility patients. Arthur also spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire’s product pipeline through investments and acquisitions.  

Earlier in his career, Arthur was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters and patents. Arthur is a member of the board of directors for gene therapy company Akouos. He serves on the Executive Committee of the Board of Directors for the Alliance for Regenerative Medicine, and on the development board for the University of New Hampshire’s College of Life Sciences and Agriculture. He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.